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ABSTRACT

The creation of an electrospun nanofiber embedded with two antibiotics that will be
used to prevent infection while also stimulating bone regeneration will be explored. The
nanofiber will contain an aminoglycoside and a glycopeptide, and it is sought to deliver a
sustained release of antibiotics for up to 12 weeks. To determine release rate, nanofiber
samples are immersed in 10.0 mL of MiliQ water (MQ), incubated at 37°C, assayed at specific
time intervals, and then analyzed using ultra performance liquid chromatography in tandem
with mass spectrometry. A hydrophilic interaction liquid chromatography (HILIC) method
utilizing ultra-performance liquid chromatography (UPLC) in tandem with mass spectrometry
(MS) has been developed in order to quantify the release rate of each antibiotic from the
nanofiber mesh as a function of time spent in MQ. The antibiotic release rate for six separate
permutations of nanofibers was documented. In addition to monitoring drug release as a
function of time, mass loss, pH changes, and morphology changes as a function of time have
been monitored for an additional three antibiotic-free permutations of nanofiber devices. More
specifically, the mass loss profiles for the three permutations of nanofiber devices were
generated. To determine mass loss, nanofiber samples are immersed in 10.0 mL of a phosphate
buffered saline (PBS), incubated at 37°C, assayed at specific time intervals, and then a final mass
was directly compared to the starting mass. Changes in morphology were documented using a
scanning electron microscope (SEM). SEM images were taken at weekly intervals and compared
to original SEM images characterizing the nanofibers before immersion in PBS.
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INTRODUCTION

Purpose
This study proposes to develop a liquid-chromatography mass-spectrometry (LC-MS)
method to determine the time-resolved elution profile of two antibiotics incorporated in to a
novel nanofiber based residue-free drug delivery device for management of orthopaedic
infections. This device will be constructed by electrospinning bioresorbable synthetic polymer
following incorporation of the antibiotics tobramycin and vancomycin. Optimization of
pharmacokinetic properties by fine tuning process parameters (drug loading, nanofiber matrix
porosity and fiber morphology) will result in controlled release of antibiotics from the device.
The proposed device will provide local antibiotic therapy at a controlled rate for up to twelve
weeks and will be resorbed following its function leaving behind healed natural bone as a
function of time. It is believed that this drug delivery device will replace antibiotic beads used as
standard of care for orthopedic infections.
The goal of the present project is to measure the rate at which antibiotics are released
by the nanofiber devices. A specific release rate can be tailored for a desired therapeutic level
via optimization of nanofiber characteristics (e.g. diameter, porosity, polymer used) and total
mass of drug loaded in the device. Release rates of tobramycin and vancomycin will be
monitored by incubation of the antibiotic-laden nanofibers under physiological conditions for
defined time steps followed by quantitation of antibiotic levels released into the fluid.
Additionally, mass loss of the nanofiber device as a function of time and morphological changes
to the nanofiber device will be analyzed.
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Existing Infection Control Methods
Following extensive orthopaedic surgery, the most typical problem facing the patient is
bacterial infection. Originally introduced in 1970 by Buchholz and Engelbrecht, acrylic bone
cement beads loaded with antibiotics are still commonly used today. The cement polymer used
for the majority of acrylic bone beads is polymethylmethacrylate (PMMA). Antibiotic-containing
PMMA beads are the most commonly used local antibiotic delivery system following
orthopaedic surgery due to the documented ability of PMMA drug delivery devices to provide
high concentrations of antibiotics to orthopaedic surgery sites that are usually poorly
vascularized (Samuel et al. 2010). Additionally, antibiotic loaded PMMA cement beads provide
high antibiotic concentrations at the infection site, but do not cause overall high levels of
antibiotics in the patient’s serum; lower levels of antibiotic in serum levels can result in a
decrease in the probability of negative side effects (Barth et al. 2011).
While antibiotic PMMA beads can provide high concentrations of antibiotics at the site
of infection, there is no definitive conclusion suggesting that antibiotic PMMA beads are actually
effective at treating and/or preventing infection following orthopaedic surgery. In order to
establish a direct connection between infection control and antibiotic PMMA beads, there
ultimately needs to be more studies involving antibiotic-containing PMMA beads, preferably
with larger sample sizes (Barth et al. 2011).
Documented negative aspects to the usage of antibiotic-containing PMMA beads
include antibiotic resistance development and the bio-incompatibility of the PMMA cement
beads themselves. The PMMA beads are not bioresorable, and therefore must be removed with
a second surgery. A second surgery can allow for the onset of additional infection. If successful,
the proposed device in this project will significantly transform the way infections are controlled;
9

the fact that the proposed nanofiber device will be bioresorbable eliminates the need for a
second surgery required by PMMA beads. As any major surgery is accompanied by inherent
risks and dangers, any opportunity to reduce the number of times a patient is operated on is
significant. Secondly, antibiotic PMMA beads are known to aid in the development of antibiotic
resistant bacteria. Bacteria have the ability to colonize on the surface of the PMMA beads,
developing a biofilm which ultimately allows the PMMA beads to support the sustained
presence of bacteria. This association between the PMMA beads and bacteria can lead to
antibiotic resistant bacteria. For example, over 65% of the bacterial strains found on gentamicin
PMMA beads removed after an orthopaedic surgery were gentamicin resistant (Barth et al.
2011).

Nanofibers Background
Nanofibers are composed of polymers ranging from biological polymers such as the
nanofiber devices in this project to synthetic polymers such as nylon. The nanofibers analyzed in
this project are electrospun nanofibers composed of poly(lactide-co-glycolide) (PLGA), a
biological polymer of lactic and glycolic acids. Nanofibers are characterized by having fiber
diameters in the several hundred nanometer range. For the sake of comparison, when
compared to human hair, the diameter of a typical nanofiber is on the order of 200-900 nm,
whereas the human hair has an average diameter of 100 µm. The SEM image below shows the
drastic size difference between a human hair and a nanofiber sample; note that the human hair
is laid atop the nanofiber sample.
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Figure 1: Human Hair vs. Nanofiber SEM Image.

Nanofiber Composition
PLGA
The nanofiber device studied is composed 50:50 poly(lactic-co-glycolic acid)
(PLGA), which is a Food and Drug Administration (FDA) approved, bioresorable copolymer of
lactic and glycolic acids. 50:50 PLGA is a PLGA copolymer composed of equal amounts of lactic
acid and glycolic acid monomers. PLGA has minimal toxicity since PLGA decomposes via
hydrolysis to lactic and glycolic acids which are physiological metabolic pathway byproducts.
During the hydrolysis of PLGA, water molecules interact directly with the ester bonds between
chains as shown in Figure 2. The degradation rate of PLGA can be altered by altering the ratio of
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lactic acid to glycolic acid; increasing the ratio of glycolide components to lactide components in
the polymer increases the rate of degradation (Kim et al. 2004).

Figure 2: Hydrolysis of PLGA. The hydrolysis of PLGA produces lactic and glycolyic acids
(Makadia et al. 2011).

Collagen
Collagens are key structural components of connective tissues such as tendons,
ligaments, cartilage, and various membranes. Specifically, type I collagen will be incorporated
into the nanofiber device proposed in this project. Overall, type I collagen is the most abundant
of all types of collagen. 90% of all bone mass in the body is attributed to type I collagen. Type I
collagen is an integral component of bone, tendon, and ligament, making it an overall important
additive in the nanofiber device. More specifically however, type I collagen is an important
component of the nanofiber device since type I collagen is responsible for many of the
biomechanical characteristics of bone including overall bone strength (Friess 1998).
Hydroxyapatite
Hydroxyapatite (HA) is a naturally occurring mineral and a common component
of both bone and teeth. The chemical formula for HA is Ca10(PO4)6(OH)2, and therefore HA is a
12

calcium apatite with a crystal cell composed of two Ca5(PO4)3(OH) units (Gao et al. 2006). HA has
been shown to promote an increased rate of bone regeneration when incorporated into
orthopaedic surgical devices; it is suggested that HA has a role in the induction mesenchymal
cell differentiation towards osteoblasts which can ultimately lead to the formation of bone;
therefore HA is advantageous to include in the nanofiber device proposed in this project (Yang
et al. 1997).

Antibiotics
Vancomycin
Vancomycin is a glycopeptide antibiotic used to combat gram positive bacteria,
being especially useful when combating methicillin resistant staphylococci (Zhang et al. 2007).
Vancomycin works by inhibiting the cell wall formation in gram positive bacteria. The structure
of vancomycin is given below in Figure 3 along with pKa values (ChemAxon). The formula weight
of vancomycin is 1449.3 amu and is characterized by the following functional groups: carboxylic
acid, phenolic hydroxyl groups, amide groups, primary amine, and secondary amine. Overall,
vancomycin is less hydrophilic than tobramycin, but is still characterized as both hydrophilic and
polar.
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Figure 3: Vancomycin Structure and pKa Values. At physiological pH (pH 7.4) it is important to
note that vancomycin has a net charge of +1.
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Tobramycin
Tobramycin is an aminoglycoside antibiotic. Tobramycin provides defense
against gram negative bacteria, functioning by inhibiting bacterial DNA replication, specifically
the translation of bacterial mRNA. Tobramycin is particularly effective against Pseudomonas
aeruginosa. Aminoglycoside antibiotics are both nephrotoxic, harmful to the kidneys, and
ototoxic, harmful to the ears (Barth et al. 2011). The formula weight for tobramycin is 467.5
amu. The structure of tobramycin along with the respective pKa values for each amine group is
shown below in Figure 4 (ChemAxon). From Figure 4, it is obvious that tobramycin is both polar
and hydrophilic. Additionally, from the amine groups present, tobramycin is considered basic.

7.75

13.8
5
13.13

9.26

8.83

12.54

8.40

9.83

Figure 4: Tobramycin Structure with pKa Values. At pH 7.4 tobramycin has a net charge of +5.
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Phosphate-Buffered Saline (PBS)
In an attempt to mimic physiological conditions, a phosphate buffered saline solution
was used. PBS is isotonic to human cells, containing ions such as K+, Cl-, Na+, and H2PO4-, and
HPO42-, and has a pH near the physiological pH of 7.4. Cellgro® PBS (cat. No. 21-030) with pH
7.0±0.1 and osmolality of 285±15 mOsm was purchased and used throughout the project. The
composition of the PBS is given in Table 1.

Table 1: PBS Cat. No. 21-030 1X, Liquid
Inorganic Salts

Concentration (g/L)

CaCl2 (anhydrous)

0.10

KCl

0.20

KH3PO4

0.20

MgCl2•6H2O

0.10

NaCl

8.00

Na2HPO4•7H2O

2.1716

Analytical Techniques
To quantify the release rate of two antibiotics, tobramycin and vancomycin, from an
electrospun nanofiber mesh this project utilized ultra performance liquid chromatography in
tandem with mass spectrometry. Liquid chromatography was chosen specifically because the
antibiotics will be eluted into a liquid matrix and in order to properly quantify the
concentrations of each individual antibiotic, the two antibiotics will need to be separated from
16

both the matrix and one another. Ultra performance liquid chromatography (UPLC) is similar to
high performance liquid chromatography (HPLC) in principle, but UPLC provides increases in
sensitivity and resolution while decreasing run time. To do so, UPLC uses higher pressures
compared to HPLC and smaller particle size in columns.
The first step in the separation process is the introduction of the sample containing both
analytes into the mobile phase. The mobile phase carries the analytes to the column, where
they are retained for a given period of time, and then, usually accompanied by a change in
mobile phase composition (though not always necessary), the analytes exit the column
separately based on each analyte’s polarity. After the analytes are separated, the analytes are
transferred to a detector. The Figure 5 below is a diagram of the separation process using UPLC.

Column

Mobile Phase
Resivoir

Computer

Sample
Detector

Pump (solvent
delivery system)

Waste
Figure 5: UPLC Schematic. (obtained from Waters Beginner Guide to UPLC;
http://www.waters.com/waters/en_US/Chromatographic-Bands%2C-Peaks-and-BandSpreading/nav.htm?cid=134803614)
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For the purposes of this project, the detector is a triple quadrupole mass spectrometer.
Mass spectrometry allows for the quantification of analytes based on their mass to charge ratio.
Each analyte is first ionized via high voltages using a soft ionization technique known as
electrospray ionization. The ionized analytes are accelerated into the first quadrupole (Q1). The
first quadrupole serves as the first mass filter based on the analyte’s given mass to charge ratio
(m/z). The ionized analytes filtered through Q1 are denoted the parent ions. The second
quadrupole (q2) is the collision chamber; here the selected analytes that pass through Q1 collide
with an inert gas, in this case argon gas, inducing fragmentation of the parent ions. The
fragmented ions, or daughter ions, are accelerated into the third quadrupole (Q3) where an
additional mass filtering occurs.

Figure 6: Triple Quadrupole Mass Spectrometry Overview.

For this project, multiple reaction monitoring (MRM) was employed in order to provide
lower detection limits, thus increasing the sensitivity of the assay by increasing the specificity of
the mass filtering process in Q3. MRM provides lower detection limits and increased sensitivity
through the specified filtering of all ions in Q3 except a selected daughter ion, providing a single,
specific mass transition that is arguably unique for an analyte. Only this specific transition is
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detected, which leads to increased sensitivity and a decrease in noise. A schematic of MRM/MS
is shown below.

Figure 7: Schematic of Multiple Reaction Monitoring.

Hydrophilic Interaction Liquid Chromatography (HILIC)
Hydrophilic interaction liquid chromatrography (HILIC) is a relatively new
chromatography method that allows for the separation of polar analytes. Due to the polarity of
both analytes, specifically Tobramycin, this study employed the usage of HILIC. In HILIC the
stationary phase is polar, allowing for retention of polar analytes. Typical stationary phase
particles include silica, amino, or cyano (Buszewski et al. 2011). Because the retention of polar
analytes increases with decreasing polarity of the mobile phase, the typical separation method
is a mobile phase gradient ranging from a low polarity organic solvent to a highly polar aqueous
solvent. Analytes are separated from the stationary phase in order of increasing polarity.
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Methods and Materials
UPLC-MS/MS Method
Using a Waters Acquity ultra performance liquid chromatograph interfaced to a Quattro
Micro triple quadrupole mass spectrometer (UPLC-MS), an assay was developed in order to
quantify Tobramycin and Vancomycin. The antibiotics were analyzed in the positive ion
electrospray mode (ESI+). In addition multiple reaction monitoring (MRM) detection was
employed in order to decrease sample noise. For the purpose of analysis, the parent ion for
tobramycin was found to be 468.0 m/z, signifying the singly protonated, [M+H]+, parent ion, and
the parent ion for vancomycin was determined to be 725.8 m/z, or the doubly protonated
[M+2H]+2 parent ion. The MRM transition for tobramycin was determined to be 468.4 m/z to
163.0 m/z, and the MRM transition for vancomycin was determined to be 725.8 m/z to 144.3
m/z. Figure 8 shows a sample mass spectrum of a 50 ppm vancomycin and tobramycin solution
in MQ. Figures 9 and 10 show the fragmentation for vancomycin and tobramycin displaying
both the parent and daughter ions for each antibiotic.
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TOB [M+H]+

TOB cone fragment

VCM [M+2H]2+

Figure 8: Mass spectrum of Tobramycin (468.4 m/z) and Vancomycin (725.8 m/z) obtained via
direct injection. Note 324.4 m/z is a fragment of tobramycin induced by the cone voltage.
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FIGURE 9: Daughter Ions of Vancomycin. The Vancomycin transition was determined to be
725.8 m/z to 144.3 m/z.

FIGURE 10: Daughter Ions of Tobramycin.The Vancomycin transition was determined to be
468.4 m/z to 163.0 m/z.

Due to the highly polar nature of both vancomycin and more specifically tobramycin,
traditional reverse-phase chromatography using a C18 column was unsuccessful; with reversephase chromatography, we were unsuccessful to retain tobramycin. We then turned to
hydrophilic interaction liquid chromatography (HILIC) in order to provide better retention for
tobramycin. Unlike in reverse-phase chromatography, in HILIC the aqueous solvent is considered
22

the strong solvent. A Waters BEH amide column was used. The BEH amide column ligand type is
a trifunctional amide, which provides retention for highly polar analytes such as tobramycin.
In order to accurately determine peak areas, baseline separation of vancomycin and
tobramycin had to be obtained. To do so, the mobile phase composition and gradient along with
the sample diluent were optimized. Quantitation is based on external calibration curves using
integrated peak areas. For the purposes of method development, pure antibiotic standards are
dissolved in 75 Acetonitrile:25 MiliQ Water:0.1 Formic Acid. Mobile phase A is 0.1% Formic Acid
in MiliQ Water. Mobile phase B is 0.1% Formic Acid in Acetonitrile. Table 2 shows the optimized
gradient, and Figure 11 is a sample chromatogram with attached gradient profile displaying the
percent of mobile phase B as a function of time. It is important to note that from Figure 11, as
the percent composition of mobile phase B decreases, both analytes are eluted from the BEH
column. All solvents are Fisher Optima brand, the highest purity and a requirement of high
quality LC-MS work. The method is shown to be linear from 1 – 5 ug/mL. The limit of detection
(LOD) for both vancomycin and tobramycin is 500 ng/mL.
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Table 2: Optimized gradient for LC-MS
Flow Rate

Time (min)

% Mobile Phase B

(mL/min)
0.4

0.0

60

0.4

0.4

60

0.4

1.0

20

0.4

2.0

20

0.4

2.01

60

0.4

4.0

60

FIGURE 11: Sample Chromatogram (9.5 ppm each analyte) and Optimized Mobile Phase
Gradient.

24

Figures 12 and 13 are sample standard calibration curves for tobramycin and vancomycin
respectively.

Figure 12: Calibration Curve for Tobramycin using 500 ppb, 5 ppm, and 10 ppm standards.

Figure 13: Calibration Curve for Vancomycin using 500 ppb, 5 ppm, and 10 ppm standards.
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Antibiotics Study
Six different permutations of electrospun nanofiber devices were received from eSpin, a
local Chattanooga company, in order to analyze the release rate of antibiotic as a function of
time. The compositions of the six devices are displayed in Table 3 below.

Table 3: Nanofiber Permutations for Antibiotic Study
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Upon receipt of the nanofiber permutations, approximately a 50 mg square was cut
from each permutation, and the exact mass of each was recorded, as displayed in Table 4.
Table 4: Mass of Nanofibers for Antibiotic Study

Cut and massed nanofiber squares were submerged in 10.0 mL of MiliQ Water (MQ) and
incubated at 37°C in order to mimic physiological conditions. In the future, after the solid phase
extraction method (SPE) is optimized, this process should be repeated with a phosphate
buffered saline (PBS) in replacement of MQ Water. The SPE process is crucial in order to remove
primarily phosphate which is present in PBS seeing as phosphate is not volatile and thus cannot
enter the mass spectrometer Ideally, samples should be assayed at specific time intervals
ranging from 0 hours to 12 weeks, but after experiencing numerous battles with computer
failure and instrument failure, the antibiotic study came to a halt, and data was only collected
until the 380 hour mark. At the given time interval, the MQ water, containing the eluted
antibiotic(s), is decanted into a separately labeled micro-centrifuge tube, and a fresh 10.0 mL of
MQ water is added to the tube containing the nanofiber sample. Then, the nanofiber sample is
placed back in the incubator until the next time interval. Samples were then analyzed using the
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UPLC-MS/MS method as described previously; elution profiles for each nanofiber permutation
were then generated.

Mass Loss, pH Study, and Morphological Changes
The experimental methods for the mass loss study were almost identical to those of the
antibiotics release rate study. For the mass loss study, three permutations of the nanofiber
device were received and tested; the compositions of the three nanofiber devices are listed in
Table 5 below.

Table 5: Mass Loss Nanofibers
Sample Name

Composition

Notes

13B1290S1

99.5% PLGA(50/50) + 0.5% HA

0.8 mm thick

13B1296S1

80% PLGA(50/50) + 19.5%

0.3 mm thick

Collagen + 0.5% HA
14B2076

80% PLGA (50/50) +

1 mm thick

20%Collagen

Alternating layers

After the three nanofiber devices were received, 12 squares were cut from each permutation, to
total 36 squares of nanofiber in all. Each square was approximately 50 mg. The original mass of
each square was recorded, and each nanofiber square was placed in 10.0 mL of PBS; samples
were then incubated at 37°C for a designated period of time. After one week, the PBS for each
sample was replaced with a fresh aliquot of 10.0 mL of PBS, and the pH of the decanted PBS was
28

measured. One sample from each nanofiber permutation was removed from the PBS and
allowed to dry. This was denoted the “week one” mass loss sample. Once the nanofiber sample
was completely dry, a final mass was recorded and compared to the original starting mass in
order to obtain a percent mass loss overall after one week. This process was repeated for a total
of 12 weeks; a mass loss profile was generated for each nanofiber permutation over the course
of 12 weeks, and simultaneously the pH of the PBS was monitored each week to ensure the
nanofiber sample was subjected to physiological pH conditions.
After the mass loss data was collected, morphological changes to the nanofiber sample
was studied via scanning electron microscopy (SEM); ultimately, the overall goal of monitoring
morphological changes to the nanofiber device is an effort to better understand the changes to
fiber shape and porosity, including inter-strand porosity and intra-strand porosity, along with
fiber integrity as a function of time in physiological conditions. To do so, samples are gold
coated and then imaged in the SEM. These images were then compared to images of the
original nanofiber without exposure to physiological conditions.
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Results and Discussion
Antibiotics Study
Figures 14 and 15 below show the established elution profiles for both vancomycin and
tobramycin as a function of time represented as antibiotic peak area counts as a function of
time.

Figure 14: Tobramycin release rate as a function of time in MiliQ Water.
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Figure 15: Vancomycin release rate as a function of time in MiliQ water.

Sample 13-B1-122-02, consisting of only PLGA and tobramycin, shows little to no release
of tobramycin throughout the first 380 hours. Sample 13-B1-122-06, also containing only
tobramycin, shows a large initial release of antibiotics followed by a small release around the 20
hour time point. The notable difference between sample 13-B1-122-02 and 13-B2-122-06 is the
presence of both collagen and hydroxyapatite in 13-B2-122-06; the presence of collagen and
hydroxyapatite is seemingly linked to a large initial burst of tobramycin. The two samples
without tobramycin, containing only vancomycin, were 13-B1-122-03 and 13-B1-122-07; 13-B1122-03 does not contain hydroxyapatite or collagen, and displays a larger overall release of
vancomycin than 13-B1-122-07 which does contain hydroxyapatite and collagen. 13-B1-122-08
31

consists of PLGA, HA, and both tobramycin and vancomycin; 13-B1-122-08 displays little to no
release for tobramycin, and small releases of vancomycin, with a notable increase in release
between the 260-380 hour time points. Lastly sample 13-B1-808-1A, composed of PLGA,
collagen, HA, tobramycin, and vancomycin, gave a large initial release of tobramycin and
vancomycin; after the initial burst of tobramycin, little to no tobramycin was released. For
sample 13-B1-808-1A, the initial release of vancomycin is accompanied by a secondary, larger
release of antibiotic, and then followed by only small releases of antibiotic. Table 6 below
summarizes the antibiotic elution rates for both antibiotics in all six permutations of nanofiber
devices received.
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Table 6: Antibiotic Elution Summary

Results obtained from the antibiotic study are similar to previously documented elution
rates from other nanofiber device studies. One study involving the incorporation of Mefoxin®, a
hydrophilic antibiotic, into a nanofiber scaffold, reports large initial bursts of antibiotic in which
the majority of the antibiotic was released within the first hour (Kim et al. 2004). Similarly
another study reported almost 90% of the incorporated gentamicin, an aminoglycoside
antibiotic, in a nanofiber scaffold was eluted within the first hour (Sirc et al. 2012). Suggested
rationale for this rapid release is due to the adsorption of the hydrophilic antibiotics to the
surface of the nanofiber mesh (Kim et al. 2004). Documented observations by eSpin stating the
difficultly incorporating the antibiotics into the nanofiber mesh accompanied by the rapid
release of antibiotic suggest that antibiotics in this study, particularly tobramycin, are simply
adsorbed to the nanofiber mesh surface instead of being incorporated into the mesh.
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Mass Loss Study
The results of the mass loss study are shown below in Figure 16. 13B1290S1 is the
slowest of the three fibers to degrade, suggesting that the presence of collagen speeds up the
rate of degradation as displayed in both 14B2076 and 13B1296S1. 14B2076 and 13B1296S1
display similar mass loss profiles, suggesting that the presence of hydroxyapatite has little
impact on degradation as to be expected.

Figure 16: Mass loss of 14B2076, 13B1296S1, and 13B1290S1 as a function of time in PBS.
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As seen in Figure 17 above, there appears to be an increase in mass in multiple samples,
primarily in later weeks. This is believed to be due to inadequate drying time of the nanofiber
sample. Ultimately the drying technique of the samples needs to be optimized and the overall
mass loss study repeated with this optimized technique.

pH Study
As mentioned previously, pH changes were also monitored in addition to mass loss.
Shown below is a graph displaying the change in pH as a function of time in PBS (Figure 16). The
pH remains fairly constant in the 13B1290S1 samples, until week 10; the pH drop is most likely
due to increased degradation, seeing as this corresponds to the dramatic mass loss represented
in Figure 16 above. It is important to note that the degradation of PLGA yields both lactic and
glycolic acids which could cause a decrease in pH with the overall increase of acidity.
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Figure 17: pH of PBS as a function of nanofiber incubation time.

Morphological Changes
Using a scanning electron microscope, morphological changes to the nanofiber mesh for
each nanofiber mesh permutation was documented as a function of incubation time. Figure 18
below is the week 0 SEM image for sample 14B2076; it is important to note that this sample of
14B2076 has not been exposed to PBS. The unperturbed 14B2076 sample is characterized by
spherical accretions, most likely consisting of collagen, and varying pore size, and varying fiber
diameter. As the 14B2076 sample is exposed to physiological conditions, the fibrous nature of
the nanofiber mesh is lost as the strands fuse together to produce a matte, and there is a
notable increase in inter-strand porosity. The effects of exposure to physiological conditions on
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14B2076 are shown in the week 2, week 5, and week 10 samples in Figures 19, 20, and 21
below.

Figure 18: 14B2076 Week 0 SEM Image .

Figure 19: 14B2076 Week 2 SEM Image.

Figure 20: 14B2076 Week 5 SEM Image.

Figure 21: 14B2076 Week 10 SEM Image.
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The 13B1296S1 sample at week 0 contains large, flat, ribbon-like strands, most likely
composed of collagen, and is characterized by small inter-strand pores. Figure 22 shows the
week 0 sample for 13B1296S1. As 13B1296S1 is exposed to physiological conditions, intra-strand
pore size increases dramatically and similarly to 14B2076 there is an overall loss of fibrous
nature; however in the case of 13B1296S1, the loss of fibrous nature is due to fiber splitting,
creating a budding effect.

Figure 22: 13B1296S1 Week 0 SEM Image

Figure 23: 13B1296S1 Week 2 SEM Image

Figure 24: 13B1296S1 Week 5 SEM Image

Figure 25: 13B1296S1 Week 10 SEM Image
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The 13B1290S1 sample at week 0 is extremely uniform with average fiber diameter of
0.5-1.0 microns. As 13B1290S1 is exposed to physiological conditions, intra-strand and interstrand pore sizes increase, and again there is an overall loss of fibrous nature due to fiber
splitting, similar to the splitting shown in 13B1296S1. By week 10, sample 13B1290S1 is difficult
to retrieve and image due to dramatic mass loss resulting in extreme fragmentation; at this
point, there is no remaining fibrous nature in the sample as it appears matte-like.

Figure 26: 13B1290S1 Week 0 SEM Image

Figure 27: 13B1290S1 Week 2 SEM Image
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Figure 28: 13B1290S1 Week 5 SEM Image

Figure 29: 13B1290S1 Week 10 SEM Image
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Comments and Future Work
In the future, the primary goal is to revisit the antibiotic release rate study. As soon as
the SPE method is optimized, the antibiotic study needs to be revisited. With an optimized SPE
method it will be possible to conduct the entire antibiotic elution study using PBS instead of MQ,
ultimately providing more accurate data since the PBS more closely mimics physiological
conditions.
Currently, a pilot study on rabbits with the three nanofiber permutations listed in Table
5 is underway. Upon the results of the rabbit study, the mass loss study will be revisited as well.
The most successful nanofiber permutation determined from the rabbit study will be extensively
analyzed. The mass loss of this nanofiber permutation as a function of time will be documented.
The samples in the future mass loss study will be done in triplicate and will be subjected to the
optimized drying procedure.
Lastly, the rapid elution of antibiotics needs to be addressed via nanofiber device
modifications. The ideal elution profile includes a large initial burst of antibiotics shortly after
surgery in order to prevent a bacterial infection from colonizing followed by a sustained release
of antibiotics to combat the remaining bacteria not eliminated with the initial antibiotic release
(Kim et al. 2004). To obtain a more sustained release of antibiotics, nanofiber diameter could be
increased, or the nanofiber mesh thickness could be increased (Kim et al. 2004). By increasing
the nanofiber mat thickness, the porosity of the overall mesh decreases, allowing for greater
retention of antibiotics (Sirc et al. 2012). Additionally, the usage of buffering nanofiber cover
meshes could be employed, essentially creating a layered nanofiber mesh. A multi-layered
nanofiber device with thicker covering layers could further increase antibiotic retention,
allowing for a more sustained release (Sirc et al. 2012).
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